Occult renal cell carcinoma manifesting with epistaxis in a woman: a case report by Fyrmpas, Georgios et al.
CASE REPORT Open Access
Occult renal cell carcinoma manifesting with
epistaxis in a woman: a case report
Georgios Fyrmpas
1*, Ade Adeniyi
2, Simon Baer
1
Abstract
Introduction: Metastatic disease in the sinonasal region occurs rarely and the primary site may be elusive. This
case highlights the possibility of an occult renal tumor manifesting with nasal symptoms and the risk of severe
bleeding following nasal biopsy.
Case presentation: We report the case of a 79-year-old Caucasian woman who presented with a six-week history
of intermittent left-sided nosebleeds. She was fit, without previous surgery or anticoagulation. Nasal endoscopy
and computed tomography showed a hemorrhagic mass occupying her left ethmoid cells and middle meatus.
After a highly hemorrhagic biopsy, the lesion was histologically confirmed as clear cell carcinoma. Screening
revealed a right kidney mass with widespread metastases. Palliative radiotherapy to the sinonasal metastasis and
systemic treatment rendered her free of symptoms nine months after initial presentation.
Conclusions: General practitioners and ear, nose and throat (ENT) doctors are very often confronted with epistaxis.
A small minority of patients with epistaxis show a primary or metastatic nasal mass. Detection of the origin of
secondary sinonasal masses requires a high index of suspicion and examination of infraclavicular sites by a
multidisciplinary team. Renal cell carcinoma metastases are prone to severe bleeding during any surgical
intervention, therefore, preoperative embolization is recommended. Resection or radiotherapy to the sinonasal
metastasis of renal origin is justified in order to prevent recurrent nosebleeds.
Introduction
Epistaxis is a common complaint that usually responds
to conservative measures. Failure to control epistaxis
after coagulopathies have been excluded should raise the
suspicion of a nasal tumor. Nasal malignant tumors are
usually primary and account for 0.3% of all neoplasms
and 3% of all head and neck neoplasms [1]. Occasionally
metastatic sinonasal tumors from infraclavicular sites,
mainly the kidneys and, to a lesser degree, the lungs and
breast, may manifest with nasal symptoms [2]. Up to the
present 105 cases of maxillary metastases and 21 cases
of ethmoid metastases from renal carcinomas have been
reported [3].
T h ea i mo ft h i sr e p o r ti st od e s c r i b ear a r ec a s eo f
occult renal cell carcinoma (RCC) presenting with mas-
sive epistaxis due to a nasal cavity-ethmoid metastasis.
The diagnostic difficulties and the current treatment
options for metastatic renal cell carcinoma to the sino-
nasal region will be briefly discussed.
Case presentation
A 79-year-old Caucasian woman presented to our ENT
department with a six-week history of recurrent pro-
gressive left-sided epistaxis. Her medical history was
negative for hypertension, diabetes mellitus, surgery,
bleeding tendencies and anticoagulation treatment.
Laboratory tests showed marginally low haemoglobin
levels (10 mg/dl) and normal calcium and lactate dehy-
drogenase (LDH) levels. On nasal endoscopy, a highly
vascular mass arising from the left middle meatus was
noted (Figure 1). Computed tomography (CT) of the
nose and paranasal sinuses revealed an expanding mass
in the left nasal cavity invading the ethmoids and
extending to the floor of the left frontal sinus (Figure 2).
A biopsy of the nasal mass under general anaesthesia
resulted in profuse intra-operative bleeding, which
necessitated anterior and posterior nasal packing. Histo-
logical examination of the specimen confirmed clear cell
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mass on the upper pole of the right kidney, measuring
65×63×99 mm, was noted on ultrasound examination
(Figure 3). Surprisingly, urine examination was negative
for haematuria. CT screening revealed widespread sec-
ondaries. Treatment with palliative radiotherapy and
immunotherapy was instituted due to our patient’s refu-
sal of any interventional treatment. She remains asymp-
tomatic nine months after initial diagnosis.
Discussion
RCC grows slowly and becomes manifest after a consid-
erable tumor size is reached. Therefore, many small and
asymptomatic RCCs are incidentally detected on ultra-
sound examination for other conditions. Thirty percent
of patients present with a distant metastasis [4] and only
10% exhibit the classical presentation of the tumor with
flank pain, palpable mass and gross haematuria [5].
Intermittent haematuria, however, may be present in
90% of patients [5]. The most common sites of distant
metastases of RCC are the abdomen, lungs, brain, liver,
adrenal glands and bones [6]. Supraclavicular metastases
usually occur in the thyroid gland, brain and very rarely
the nose and paranasal sinuses. RCC tumor cells spread
to the sinonasal region via two potential haematogenous
routes: a) the route that follows the inferior vena cava,
lungs, heart and the maxillary artery, in which case con-
current lung or brain metastasis may be present, and
b) the route through the communication of the avalvular
vertebral venous plexus and the intracranial venous
plexous; in such case the sinonasal region may be the
only site of metastasis [7].
RCC comprises a histologically diverse group of solid
tumors; the most common histological variant being the
clear cell RCC (85%) [8]. This variant is associated with
loss of function of the von Hippel Lindau gene which
leads to upregulation of the hypoxia inducible factor
(HIF) and, finally, increased function of the vascular
endothelial growth factor (VEGF) [9]. The net effect of
this chain of events is increased angiogenesis and vascu-
larity of clear cell RCC and related metastases. There-
fore, sinonasal metastases of RCC origin are
characterized by a propensity for severe bleeding [10].
A differential diagnosis of nasal bleeding lesions
should include angiofibromas, hemangiopericytomas,
hemangiomas and other less vascular malignant lesions
such as adenocarcinomas, melanomas and metastatic
tumors from the breast and lungs. A paranasal sinus CT
scan may provide some hints about the benign or
Figure 1 Endoscopic view of hemorrhagic lesion protruding
through the left middle meatus.
Figure 2 Axial CT scan of the nose and paranasal sinuses
showing that the lesion occupies the left nasal cavity and
ethmoid sinuses.
Figure 3 Ultrasound examination reveals a large mass on the
upper pole of the patients’ right kidney.
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remodeling (signs of malignant and metastatic lesions),
hypervascularity, expansion of the sphenopalatine fora-
men and pterygopalatine fossa (angiofibromas). Mag-
netic resonance imaging (MRI) shows the true extent of
the lesion, infiltration of the skull base and leptomenin-
geal metastases. Biopsy of a suspicious nasal lesion is
imperative to guide further workup, but severe hemor-
rhage may occur [11]. Some authors advocate selective
embolization prior to tumor biopsy particularly if there
is a known history of nephrectomy [10,12]. Biopsy of
RCC nasal metastasis may prove non-diagnostic due to
diffuse necrosis of the lesion so several attempts are
sometimes necessary [11]. If the histological specimen
shows clear cells, the abdomen should be investigated
with ultrasonography and CT. Other sites prone to RCC
metastasis, such as the lungs, brain and bone, should be
screened with CT and bone scintigraphy, respectively.
Patients with metastatic RCC have a poor prognosis
with a median survival of seven to 11 months [4]. How-
ever, the biological behavior of RCC is variable and
prognosis depends on clinical, radiological, serological
and histological factors. Tumor stage and grade, the pre-
sence of vascular invasion and capsular infiltration,
microvessel density and tumor necrosis are important
clinicohistological prognostic factors. Low performance
status (70 or less in Karnofski’s scale), thrombocytosis,
and neutrophilia, one and a half times higher than nor-
mal levels of serum LDH, low hemoglobin, corrected
serum calcium levels higher than 10 mg/dL are poor
prognostic indicators [13].
Metastatic RCC is resistant to radiotherapy and che-
motherapy although a variable response has been
reported [4]. According to the The National Compre-
hensive Cancer Network practice guidelines for kidney
cancer [14], patients with a resectable primary tumor
and a single metastasis or post-nephrectomy patients
who develop a metachronous metastasis may benefit
from nephrectomy and metastasectomy or metastasect-
omy respectively. If the primary tumor is potentially
resectable but multiple metastases coexist, cytoreductive
nephrectomy and systematic therapy is likely to be of
benefit. Interferon a, interleukin 2, temsirolimus, suruti-
nib and bevacizumab are currently evaluated in thera-
peutic protocols. If the primary tumor is unresectable
and the nasal metastasis causes epistaxis and visual dis-
turbances, the patient may receive systemic therapy or
resection or radiotherapy of the metastasis.
Conclusion
Sinonasal lesions presenting with epistaxis are rare. RCC
metastases to the nasal cavity and paranasal sinuses
should be included in the differential diagnosis of nasal
bleeding lesions. Biopsy and resection of such lesions
may result in profuse bleeding and, therefore, pre-opera-
tive embolization is recommended. RCC sinonasal
metastasis signifies advanced disease with compromised
survival. Resection or radiotherapy of the nasal metasta-
sis with palliative intent will improve quality of life and
the choice of treatment modality depends upon the
patient’s physical status and preference.
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